Benefits
Cardiovascular protection
Reduces LDL oxidation, inhibits platelet aggregation, improves endothelial function, and modestly lowers blood pressure. Partly attributed to the 'French Paradox' of low CVD rates in red wine-consuming populations.
Sirtuin activation and longevity
Activates SIRT1 deacetylase, mimicking caloric restriction signaling. This upregulates mitochondrial biogenesis, improves metabolic efficiency, and activates stress resistance pathways.
Anti-inflammatory effects
Inhibits NF-κB transcription factor, reducing production of inflammatory cytokines (TNF-α, IL-6, IL-1β) and COX enzymes. Clinically shows reduced CRP levels in metabolic syndrome patients.
Blood sugar regulation
Improves insulin sensitivity through SIRT1/AMPK activation and reduces postprandial glucose spikes. RCTs in type 2 diabetes show modest improvements in HbA1c and fasting glucose.
Postmenopausal pain, vasomotor symptoms, and bone metabolism
The 24-month RESHAW trial (Resveratrol Supporting Healthy Aging in Women) — the longest resveratrol study to date — demonstrated that 75 mg twice daily in 125 postmenopausal women produced significant reductions in pain perception, vasomotor symptoms (hot flushes, night sweats), somatic symptoms (joint and muscle discomfort), sleep disturbance, and improved overall quality of life. A 2025 systematic review of 10 RCTs (928 participants) confirmed significant improvements in pain scores and bone resorption marker CTX, though effects on general menopausal symptoms varied across studies. Mechanism is partly via estrogen receptor binding (resveratrol acts as a phytoestrogen) and improved cerebrovascular function.
Mechanism of action
SIRT1 deacetylase activation
Resveratrol directly binds and allosterically activates SIRT1, promoting deacetylation of PGC-1α (mitochondrial biogenesis), FOXO transcription factors (stress resistance), and p53 (DNA damage response).
AMPK pathway stimulation
Resveratrol inhibits mitochondrial ATP synthase at low concentrations, transiently raising AMP:ATP ratio and activating AMPK — improving glucose uptake, fatty acid oxidation, and mitochondrial function.
Estrogenic activity
Resveratrol is a phytoestrogen that binds estrogen receptors (ERα and ERβ) with preferential affinity for ERβ, producing tissue-selective estrogenic effects relevant to bone, brain, and cardiovascular tissue.
Clinical trials
Clinical trial of 150 mg/day resveratrol vs placebo in 11 obese but healthy men over 30 days. Outcomes: energy expenditure, mitochondrial function, HOMA-IR, lipids. (Cell Metab)
11 obese healthy men (very small).
Resveratrol modestly affected metabolic parameters — reduced sleeping metabolic rate, improved mitochondrial function, lowered HOMA-IR, reduced triglycerides and inflammatory markers. Critical caveat: very small trial (n=11); the dramatic 'caloric restriction mimetic' framing rests on limited human data. Subsequent larger trials have been mixed.
Evidence review and pooled analysis of 11 clinical trials examining resveratrol in T2DM patients. (Liu et al. 2014, Am J Clin Nutr; or related)
Pooled across 11 T2DM clinical trials.
Modest reductions in fasting glucose, HbA1c, insulin resistance, systolic BP. Effect sizes modest. Note: T2DM management uses metformin, GLP-1 agonists, SGLT-2 inhibitors as evidence-based first-line — resveratrol adjunctive at most.
24-month, randomized, double-blind, placebo-controlled, two-period crossover trial (RESHAW) of resveratrol (75 mg twice daily, 150 mg/day) vs placebo in postmenopausal women. Outcomes: pain, vasomotor symptoms, cognition, BMD.
Postmenopausal women. 24-month long-term.
Resveratrol modestly improved pain perception, vasomotor symptoms (hot flushes), and cognitive measures vs placebo. Notable long-term trial — most resveratrol research is shorter. Modest effects.